These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 8782740)

  • 41. Binding of BCR/ABL junctional peptides to major histocompatibility complex (MHC) class I molecules: studies in antigen-processing defective cell lines.
    Cullis JO; Barrett AJ; Goldman JM; Lechler RI
    Leukemia; 1994 Jan; 8(1):165-70. PubMed ID: 8289483
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Major histocompatibility complex (MHC) class I and class II proteins: impact of polymorphism on antigen presentation.
    Abualrous ET; Sticht J; Freund C
    Curr Opin Immunol; 2021 Jun; 70():95-104. PubMed ID: 34052735
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Enhancement to the RANKPEP resource for the prediction of peptide binding to MHC molecules using profiles.
    Reche PA; Glutting JP; Zhang H; Reinherz EL
    Immunogenetics; 2004 Sep; 56(6):405-19. PubMed ID: 15349703
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Nonclassical HLA-G molecules are classical peptide presenters.
    Diehl M; Münz C; Keilholz W; Stevanović S; Holmes N; Loke YW; Rammensee HG
    Curr Biol; 1996 Mar; 6(3):305-14. PubMed ID: 8805247
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Tumor-derived heat shock protein 70 peptide complexes are cross-presented by human dendritic cells.
    Noessner E; Gastpar R; Milani V; Brandl A; Hutzler PJ; Kuppner MC; Roos M; Kremmer E; Asea A; Calderwood SK; Issels RD
    J Immunol; 2002 Nov; 169(10):5424-32. PubMed ID: 12421917
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Recognition of core and flanking amino acids of MHC class II-bound peptides by the T cell receptor.
    Sant'Angelo DB; Robinson E; Janeway CA; Denzin LK
    Eur J Immunol; 2002 Sep; 32(9):2510-20. PubMed ID: 12207335
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pathways for the processing and presentation of antigens to T cells.
    Monaco JJ
    J Leukoc Biol; 1995 Apr; 57(4):543-7. PubMed ID: 7722412
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immunodominance across HLA polymorphism: implications for cancer immunotherapy.
    Kim CJ; Parkinson DR; Marincola F
    J Immunother; 1998 Jan; 21(1):1-16. PubMed ID: 9456431
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Enhanced susceptibility to cytotoxic T lymphocytes without increase of MHC class I antigen expression after conditional overexpression of heat shock protein 70 in target cells.
    Dressel R; Lübbers M; Walter L; Herr W; Günther E
    Eur J Immunol; 1999 Dec; 29(12):3925-35. PubMed ID: 10602000
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Structure of peptides associated with class I and class II MHC molecules.
    Engelhard VH
    Annu Rev Immunol; 1994; 12():181-207. PubMed ID: 7516668
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Structural prediction of peptides binding to MHC class I molecules.
    Bui HH; Schiewe AJ; von Grafenstein H; Haworth IS
    Proteins; 2006 Apr; 63(1):43-52. PubMed ID: 16447245
    [TBL] [Abstract][Full Text] [Related]  

  • 52. MHC-BPS: MHC-binder prediction server for identifying peptides of flexible lengths from sequence-derived physicochemical properties.
    Cui J; Han LY; Lin HH; Tang ZQ; Jiang L; Cao ZW; Chen YZ
    Immunogenetics; 2006 Aug; 58(8):607-13. PubMed ID: 16832638
    [TBL] [Abstract][Full Text] [Related]  

  • 53. MHC class I antigen presentation--recently trimmed and well presented.
    Flutter B; Gao B
    Cell Mol Immunol; 2004 Feb; 1(1):22-30. PubMed ID: 16212917
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Understanding the drivers of MHC restriction of T cell receptors.
    La Gruta NL; Gras S; Daley SR; Thomas PG; Rossjohn J
    Nat Rev Immunol; 2018 Jul; 18(7):467-478. PubMed ID: 29636542
    [TBL] [Abstract][Full Text] [Related]  

  • 55. HLA-E and HLA-E-bound peptides: recognition by subsets of NK and T cells.
    Pietra G; Romagnani C; Moretta L; Mingari MC
    Curr Pharm Des; 2009; 15(28):3336-44. PubMed ID: 19860683
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Invariant chain as a vehicle to load antigenic peptides on human MHC class I for cytotoxic T-cell activation.
    Wälchli S; Kumari S; Fallang LE; Sand KM; Yang W; Landsverk OJ; Bakke O; Olweus J; Gregers TF
    Eur J Immunol; 2014 Mar; 44(3):774-84. PubMed ID: 24293164
    [TBL] [Abstract][Full Text] [Related]  

  • 57. MHC-peptide multimers: tools of choice for detecting and sorting antigen-specific T-cells.
    Lang F; Bodinier M
    Transfusion; 2001 May; 41(5):687-90. PubMed ID: 11346707
    [No Abstract]   [Full Text] [Related]  

  • 58. Empty peptide-receptive MHC class I molecules for efficient detection of antigen-specific T cells.
    Saini SK; Tamhane T; Anjanappa R; Saikia A; Ramskov S; Donia M; Svane IM; Jakobsen SN; Garcia-Alai M; Zacharias M; Meijers R; Springer S; Hadrup SR
    Sci Immunol; 2019 Jul; 4(37):. PubMed ID: 31324690
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Differential expression of melanoma-associated antigens and molecules involved in antigen processing and presentation in three cell lines established from a single patient.
    Kovalcsik E; John J; Turner M; Birchall L; Sage D; Whittle R; Dalgleish A; Pandha H
    Melanoma Res; 2004 Dec; 14(6):463-71. PubMed ID: 15577316
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Generation and use of alternative multimers of peptide/MHC complexes.
    Hugues S; Malherbe L; Filippi C; Glaichenhaus N
    J Immunol Methods; 2002 Oct; 268(1):83-92. PubMed ID: 12213345
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.